Beyond Cas9

While CRISPR/Cas9 may be the most famous of the CRISPR gene editing approaches, other enzymes may have their niches, the Wall Street Journal says.

North Carolina State University's Rodolphe Barrangou, for instance, is using Cas3 in his work on antibiotic resistance. "Cas3 is a meaner system and more cumbersome than Cas9," he tells the Journal. "But if you want to cut a tree and get rid of it, you bring a chain saw, not a scalpel."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.